Gelesis Holdings ROE 2021-2022 | GLS
Current and historical return on equity (ROE) values for Gelesis Holdings (GLS) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Gelesis Holdings ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2022-09-30 |
$0.14B |
$-0.00B |
-175.55% |
| 2022-06-30 |
$0.10B |
$0.01B |
-111.42% |
| 2022-03-31 |
$0.01B |
$0.01B |
-6.69% |
| 2021-12-31 |
$-0.00B |
$-0.33B |
2.20% |
| 2021-06-30 |
$-0.16B |
$0.01B |
-4240.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.012B |
$0.011B |
|
Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Gelesis, formerly known as Capstar Special Purpose Acquisition Corp., is based in BOSTON.
|
